Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabiralizumab - Bristol-Myers Squibb/Five Prime Therapeutics

Next Previous
Drug Profile

Cabiralizumab - Bristol-Myers Squibb/Five Prime Therapeutics

Alternative Names: BMS-986227; Cabiralizumab; FPA-008; ONO-4687

Latest Information Update: 23 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Five Prime Therapeutics
  • Developer Bristol-Myers Squibb; Five Prime Therapeutics; NYU Langone Health; Pyxis Oncology; University of Chicago; University of Michigan Rogel Cancer Center; Yale University
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pigmented villonodular synovitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer
  • Discontinued Cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Peripheral T-cell lymphoma; Pigmented villonodular synovitis; Renal cell carcinoma; Rheumatoid arthritis; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 23 Oct 2024 Discontinued - Phase-I for Cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV)
  • 23 Oct 2024 Discontinued - Phase-I for Cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Japan (IV)
  • 23 Oct 2024 Discontinued - Phase-I for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top